NDLI: Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Schenk, Jeannette M. Till, Cathee A. Tangen, Catherine M. Goodman, Phyllis J. Song, Xiaoling Torkko, Kathleen C. Kristal, Alan R. Peters, Ulrike Neuhouser, Marian L.
Description	Author Affiliation: Schenk JM ( Fred Hutchinson Cancer Research Center, Cancer Prevention Program); Till CA ( SWOG, Statistical Center); Tangen CM ( SWOG, Statistical Center); Goodman PJ ( SWOG, Statistical Center); Song X ( Fred Hutchinson Cancer Research Center, Cancer Prevention Program); Torkko KC ( Department of Pathology, University of Colorado Denver, Aurora, Colorado.); Kristal AR ( Fred Hutchinson Cancer Research Center, Cancer Prevention Program); Peters U ( Fred Hutchinson Cancer Research Center, Cancer Prevention Program); Neuhouser ML ( Fred Hutchinson Cancer Research Center, Cancer Prevention Program)
Abstract	BACKGROUND: Epidemiologic studies have reported inconsistent associations of vitamin D and prostate cancer risk; however, few have adequately controlled for detection bias related to prostate-specific antigen (PSA) screening, and the results of many studies may be affected by occult prostate cancers among controls. METHODS: Data for this nested case-control analysis (n = 1,695 cases/1,682 controls) are from the Prostate Cancer Prevention Trial. Baseline serum was analyzed for 25-hydroxyvitamin D [25(OH)D]. The presence or absence of cancer was subsequently determined by prostate biopsy. Polytomous logistic regression models were used to estimate associations of 25(OH)D with risk of total, Gleason 2-6, Gleason 7, and Gleason 8-10 prostate cancer. Results are presented for placebo and finasteride arms separately and combined. RESULTS: There were no associations of serum 25(OH)D with total prostate cancer risk. For Gleason 2-6 cancers, results were inconsistent across treatment arms with a suggestion of increased risk in the placebo arm only; however, there was no dose-response relationship. For Gleason 8-10 prostate cancers, 25(OH)D concentrations were associated with a linear decrease in risk among combined treatment arms [quartile 4 vs. 1: OR, 0.55; 95% confidence interval (CI), 0.32-0.94; P(trend) = 0.04]. These findings were somewhat stronger among men ≥65 versus 55-64 years at baseline (quartile 4 vs. 1: OR, 0.40; 95% CI, 0.18-0.88 vs. OR, 0.73; 95% CI, 0.35-1.52, respectively; P(interaction) = 0.52). CONCLUSIONS: Higher serum 25(OH)D may modestly increase risk of Gleason 2-6 disease and more substantially reduce risk of Gleason 8-10 prostate cancer. IMPACT: Vitamin D may have different effects for different stages of prostate cancers.
File Format	HTM / HTML
ISSN	10559965
e-ISSN	15387755
DOI	10.1158/1055-9965.EPI-13-1340
Journal	Cancer Epidemiology Biomarkers & Prevention
Issue Number	8
Volume Number	23
Language	English
Publisher	American Association for Cancer Research
Publisher Date	2014-08-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Cancer epidemiology Prostatic Neoplasms Blood Prevention & Control Vitamin D Analogs & Derivatives 5-alpha Reductase Inhibitors Therapeutic Use Case-control Studies Double-blind Method Finasteride Risk Factors Randomized Controlled Trial Research Support, N.i.h., Extramural
Content Type	Text
Resource Type	Article
Subject	Epidemiology Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.

Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Associations of serum sex steroid hormone and 5 -androstane-3 ,17ß-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.

Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study.

Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.

Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).

Serum 25-hydroxyvitamin D and risk of oropharynx and larynx cancers in Finnish men.

Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.

Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial.

Similar Documents

Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.

Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Associations of serum sex steroid hormone and 5 -androstane-3 ,17ß-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.

Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study.

Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.

Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).

Serum 25-hydroxyvitamin D and risk of oropharynx and larynx cancers in Finnish men.

Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.

Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial.